Department of Pharmacy, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo, 060-8648, Japan.
Department of Breast Surgery, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo, 060-8648, Japan.
Sci Rep. 2023 Jun 7;13(1):9247. doi: 10.1038/s41598-023-36264-4.
Docetaxel-induced fluid retention (DIFR) cumulatively occurs and is one of the most troublesome adverse effects. This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast cancer patients receiving docetaxel (75 mg/m)-containing regimens were divided into 4 and 8 mg/day DEX groups, with each DEX dose administered on days 2-4 and retrospectively assessed. Incidence of greater than or equal to grade 2 DIFR was significantly lower in the 8 mg group (13.0%) compared to the 4 mg group (39.6%, P = 0.001). All-grade DIFR was also less in the 8 mg group (P = 0.01). Furthermore, the maximum variation of body weight was significantly lower in the 8 mg group (P = 0.0003). These results were also confirmed in the propensity score-matched population. Additionally, time-related DIFR incidence was also significantly delayed in the 8 mg group (P = 0.0005). Our study revealed that high dose DEX prevents DIFR. Therefore, further studies on its management are required for less onerous chemotherapy provision with better DIFR control.
多西他赛引起的液体潴留（DIFR）逐渐发生，是最麻烦的不良反应之一。本研究旨在确定高剂量地塞米松（DEX）是否可以预防乳腺癌治疗中的 DIFR。接受多西他赛（75mg/m）方案治疗的乳腺癌患者被分为 4mg/天和 8mg/天 DEX 组，每组 DEX 剂量在第 2-4 天给药，并进行回顾性评估。8mg 组≥2 级 DIFR 的发生率明显低于 4mg 组（39.6%，P=0.001）。8mg 组的所有级别 DIFR 也较少（P=0.01）。此外，8mg 组的体重最大变化明显较低（P=0.0003）。在倾向评分匹配人群中也得到了证实。此外，8mg 组的时间相关 DIFR 发生率也明显延迟（P=0.0005）。我们的研究表明，高剂量 DEX 可预防 DIFR。因此，需要进一步研究其管理方法，以便在更好地控制 DIFR 的同时，提供负担较小的化疗。
